头颈癌靶向与免疫治疗药物可负担性差异分析
该研究对比了帕博利珠单抗、纳武利尤单抗、西妥昔单抗、吉非替尼和厄洛替尼在七个不同收入水平国家的可负担性与预算覆盖情况。结果显示免疫治疗在所有国家均不可负担,而口服酪氨酸激酶抑制剂费用显著较低。
要点
- 免疫治疗在高低收入国家均超出可负担阈值。
- 吉非替尼在南亚部分国家费用低于灾难性支出阈值。
- 帕博利珠单抗治疗一例的费用可覆盖南亚18-22例吉非替尼治疗。
核心结论
- 尽管免疫治疗生存获益有限,但其定价严重限制全球可及性,需政策改革与定价策略确保公平诊疗。
研究设计与样本
- 对五种常用系统治疗药物在七个高、中高、中低收入国家进行可负担性与预算覆盖对比分析。
主要发现
- 免疫治疗在所有国家均不可负担。
- 六个月帕博利珠单抗费用占印度月收入7994%、巴基斯坦4311%、孟加拉国3133%。
- 高收入国家帕博利珠单抗费用仍超灾难性阈值:美国591%、英国903%。
- 南亚吉非替尼费用占月收入171%-412%,在巴基斯坦和孟加拉国低于阈值。
- 南亚治疗一例帕博利珠单抗的费用可资助18-22例吉非替尼治疗。
临床怎么用
- 在资源有限地区选择系统治疗时需考虑药物可负担性差异。
- 口服酪氨酸激酶抑制剂可能作为南亚部分国家更可及的替代选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The expanding use of systemic therapies for recurrent and metastatic head and neck cancer has raised major concerns regarding affordability and equitable access, particularly across countries with differing income levels and health financing structures. METHODS: We conducted a comparative affordability and budget-reach analysis of commonly used systemic agents-pembrolizumab, nivolumab, cetuximab, gefitinib, and erlotinib-across seven countries (United States, United Kingdom, Australia, South Africa, India, Pakistan, and Bangladesh) representing high-, upper-middle-, and lower-middle-income settings. RESULTS: Immunotherapy was unaffordable across all settings. Six-month pembrolizumab costs corresponded to 7994% of monthly income in India, 4311% in Pakistan, 3133% in Bangladesh, and remained above catastrophic thresholds in high-income countries (591% in the United States; 903% in the United Kingdom). In contrast, oral tyrosine kinase inhibitors were substantially less costly, with gefitinib requiring 171%-412% of monthly income in South Asia and falling below thresholds in Pakistan and Bangladesh. The cost of treating one patient with pembrolizumab could fund treatment for 18-22 patients with gefitinib in South Asia. CONCLUSIONS: Despite modest survival benefits, current immunotherapy pricing severely limits global accessibility. Policy reform and pricing strategies are needed to ensure equitable cancer care.
引用
- Singh AG, Kole L, Sullivan R, et al. Disparity in the Markers of Affordability Across Targeted- and Immune-Therapy Drugs Used in Head and Neck Cancers. Head Neck. 2026. PMID: 41748307. doi:10.1002/hed.70212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。